Core Viewpoint - Warner Pharmaceuticals reported a revenue of 1.516 billion yuan for the year 2025, marking a year-on-year growth of 7.26% and a net profit attributable to the parent company of 241 million yuan, which represents a significant increase of 46.95% [1] Revenue Growth - The increase in total revenue is attributed to the growth in sales of formulation products, active pharmaceutical ingredients, intermediates, and technical service income [1] Net Profit Analysis - The rise in net profit attributable to the parent company is primarily influenced by investment income [1] - However, the net profit excluding non-recurring gains and losses decreased due to the accrual of stock incentive expenses; after adjusting for these expenses, the net profit attributable to the parent company was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 1.516 billion yuan, representing a year-on-year increase of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a significant year-on-year growth of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, which reflects a decrease of 6.01% compared to the previous year [1] - Total assets at the end of the reporting period reached 3.053 billion yuan, marking a year-on-year increase of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, up 13.44% year-on-year [1] Performance Drivers - The increase in revenue was primarily driven by growth in sales of formulation products, raw materials, intermediate products, and technical service income [2] - The rise in net profit attributable to the parent company was mainly influenced by investment income [2] - The decline in net profit after deducting non-recurring gains and losses was attributed to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit would have been 182 million yuan, an increase of 31.57% year-on-year [2] Significant Changes in Financial Metrics - Operating profit increased by 51.53% year-on-year, while total profit rose by 51.88% [3] - The basic earnings per share grew by 47.20% year-on-year, largely due to the strategic investment and restructuring of Shanghai Zhigen Pharmaceutical Technology Co., Ltd., which resulted in the company no longer consolidating it in its financial statements [3] - The company's share capital increased by 40.00% due to a capital reserve conversion, raising the total shares from 93.8 million to 131.32 million [3]

Core Viewpoint - Warner Pharmaceutical (688799) reported a revenue of 1.516 billion yuan for the year 2025, reflecting a year-on-year growth of 7.26%, and a net profit attributable to shareholders of 241 million yuan, which represents a significant increase of 46.95% [1] Group 1 - The increase in revenue is attributed to growth in sales of formulation products, raw materials, intermediates, and technical service income [1] - The rise in net profit is primarily influenced by investment income [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, representing a year-on-year growth of 7.26%, and a net profit attributable to the parent company of 241 million yuan, which is an increase of 46.95% [1] Revenue Summary - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediate products, and growth in technical service income [1] Profit Summary - The increase in net profit attributable to the parent company was significantly influenced by investment income [1] - However, the net profit attributable to the parent company after deducting non-recurring gains and losses declined due to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.26%, and a net profit attributable to shareholders of 241 million yuan, which is a significant increase of 46.95% [1] Revenue Performance - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediates, and growth in technical service income [1] Profit Analysis - The increase in net profit attributable to shareholders was mainly influenced by investment income; however, the net profit excluding non-recurring gains and losses declined due to the accrual of equity incentive expenses [1] - After excluding the impact of equity incentive expenses, the net profit attributable to shareholders, adjusted for non-recurring gains and losses, was 182 million yuan, representing a year-on-year increase of 31.57% [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a preliminary performance summary for the fiscal year 2025, indicating a revenue increase and significant growth in net profit, driven by various product sales and investment income [1] Financial Performance - The company achieved an operating revenue of 1.516 billion yuan, representing a year-on-year growth of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a year-on-year increase of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, reflecting a year-on-year decline of 6.01% [1] Asset and Equity Growth - At the end of the reporting period, the total assets of the company reached 3.053 billion yuan, marking a year-on-year growth of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, which is a year-on-year increase of 13.44% [1] Revenue Drivers - The growth in operating revenue was primarily due to increased sales of formulation products, raw materials, intermediates, and technical service income [1] - The increase in net profit attributable to the parent company was mainly influenced by investment income [1] - The decline in net profit after deducting non-recurring gains and losses was attributed to the accrual of equity incentive expenses; excluding this impact, the adjusted net profit was 182 million yuan, which is a 31.57% increase compared to the same period last year [1]

Core Viewpoint - Warner Pharmaceuticals reported a slight increase in revenue and a significant rise in net profit for the first three quarters of 2025, indicating overall growth despite a decline in adjusted net profit [1] Financial Performance - The company achieved an operating revenue of 1.086 billion yuan, representing a year-on-year growth of 1.55% [1] - The net profit attributable to shareholders reached 207 million yuan, showing a year-on-year increase of 30.75% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 99 million yuan, reflecting a year-on-year decline of 26.52% [1] - After excluding the impact of share-based payments, the adjusted net profit attributable to shareholders was 133 million yuan, with a slight year-on-year decrease of 1.48% [1] Product Revenue Breakdown - Revenue from formulation products amounted to 805 million yuan, marking a year-on-year growth of 0.55% [1] - Revenue from raw materials and intermediates reached 262 million yuan, with a year-on-year increase of 2.06% [1]